Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.007 AUD | 0.00% |
|
+16.67% | -22.22% |
Jun. 11 | OncoSil Medical Treats Fifth Pancreatic Cancer Patient with Proprietary Device | MT |
Jun. 03 | Oncosil Medical Treats 200th Pancreatic Cancer Patient with Proprietary Device | MT |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Device Development for New Medical Treatment
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +58.63% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia and New Zealand
69.6
%
| 0 | 100.0 % | 0 | 69.6 % | +10.40% |
Europe
30.4
%
| - | - | 0 | 30.4 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Nigel Lange
CEO | Chief Executive Officer | - | 20-05-03 |
Christian Cin
DFI | Director of Finance/CFO | - | 23-05-31 |
Jon Bell
CTO | Chief Tech/Sci/R&D Officer | - | - |
Henk Tissing
CTO | Chief Tech/Sci/R&D Officer | - | - |
David Turner
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Nigel Lange
CEO | Chief Executive Officer | - | 20-05-03 |
Douglas Cubbin
CHM | Chairman | - | 23-08-06 |
Director/Board Member | - | 23-07-13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,103,954,978 | 2,808,458,184 ( 90.48 %) | 0 | 90.48 % |
Company contact information
![address OncoSil Medical Limited(OSL)](https://cdn.zonebourse.com/static/address/13329856.png)
Sector
Sales per region
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.22% | 16.16M | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |
- Stock Market
- Equities
- OSL Stock
- Company OncoSil Medical Limited